NH Governor Blocks Medical Cannabis Greenhouse Expansion Bill
Republican Governor Kelly Ayotte vetoes bipartisan legislation that would have allowed dispensaries to cultivate medical marijuana in greenhouses.
New Hampshire Governor Kelly Ayotte delivered a setback to the state's medical cannabis program by vetoing Senate Bill 468, which would have permitted licensed dispensaries to cultivate marijuana in greenhouse facilities. The Republican governor's rejection of the bipartisan measure underscores the ongoing regulatory headwinds facing cannabis operators in conservative-leaning states, even as medical programs gain broader acceptance nationwide.
The vetoed legislation, sponsored by Republican Senator Howard Pearl from Loudon, aimed to expand cultivation options for New Hampshire's limited medical marijuana dispensaries. Current state law restricts where and how licensed operators can grow cannabis, creating supply constraints that drive up costs for patients. The greenhouse provision would have provided cultivators with more efficient growing environments while potentially reducing operational expenses through improved climate control and year-round production capabilities.
Ayotte's opposition reflects the cautious approach many Republican governors maintain toward cannabis expansion, despite growing bipartisan support for medical marijuana programs. Her stance contrasts with neighboring states like Vermont and Maine, which have embraced more liberal cannabis policies. This regulatory divergence creates competitive disadvantages for New Hampshire operators while limiting patient access compared to surrounding markets.
The veto impacts the broader Northeast cannabis landscape, where state-by-state policy differences create a patchwork of opportunities and restrictions for multi-state operators. Companies like Curaleaf Holdings (OTCQX: CURLF) and Green Thumb Industries (OTCQX: GTBIF) must navigate these varying regulatory environments when planning expansion strategies. New Hampshire's restrictive approach may deter investment and limit the state's ability to capture tax revenue from cannabis commerce.
The governor's decision arrives as the federal cannabis rescheduling process remains stalled, leaving state-level policy changes as the primary driver of industry growth. With limited cultivation capacity and higher production costs, New Hampshire's medical program faces challenges competing with more established markets. The veto signals that meaningful cannabis reform in the Granite State will likely require either a change in gubernatorial leadership or sustained legislative pressure to override executive opposition.